Similarly, the metabolism of ezetimibe, an intestinal cholesterol-uptake blocker, is altered in NASH patients due to differential localization of ABCC2 and ABCB1 efflux transporters, hence, resulting in plasma retention of the active glucuronide metabolite of ezetimibe (Hardwick et al., 2012b). Here, ABCC2 is linked to metabolic dysfunction-associated steatohepatitis.